

Beyond Glycemic Control: Diabetic Complication- Targeted Therapeutic Potential of *Moringa Oleifera*

Mansi M. Gajbhiye¹

¹Bhausaheb Mulak College of Pharmacy

Publication Date: 2026/01/15

Abstract: Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia and is associated with the progressive development of microvascular and macrovascular complications. Despite the availability of conventional antidiabetic therapies, long-term management of diabetes-related complications remains a major clinical challenge due to adverse effects and limited efficacy. In recent years, medicinal plants have gained increasing attention as complementary therapeutic options owing to their safety profile and multi-targeted actions. *Moringa oleifera*, commonly known as the drumstick tree, has emerged as a promising medicinal plant with diverse pharmacological properties. Beyond its glucose-lowering potential, *Moringa oleifera* exhibits antioxidant, anti-inflammatory, nephroprotective, neuroprotective, retinoprotective, and wound-healing activities that are relevant to the management of diabetic complications. The therapeutic effects of *Moringa oleifera* are attributed to its rich phytochemical composition, including flavonoids, phenolic acids, vitamins, and bioactive glycosides. This review comprehensively discusses the role of *Moringa oleifera* in targeting major diabetic complications such as diabetic retinopathy, nephropathy, neuropathy, and impaired wound healing. Additionally, the underlying mechanisms of action and recent experimental and clinical evidence supporting its therapeutic potential are highlighted. Overall, *Moringa oleifera* represents a valuable natural candidate for adjunctive therapy aimed at preventing and managing diabetes-associated complications beyond glycemic control.

Keywords: *Moringa Oleifera*, *Diabetes Mellitus*, *Diabetic Complications*, *Oxidative Stress*, *Herbal Medicine*.

How to Cite: Mansi M. Gajbhiye (2026) Beyond Glycemic Control: Diabetic Complication- Targeted Therapeutic Potential of *Moringa Oleifera*. *International Journal of Innovative Science and Research Technology*, 11(1), 703-713.
<https://doi.org/10.38124/ijisrt/26jan112>

I. INTRODUCTION

Diabetes mellitus (DM) is a complex metabolic disorder marked by chronic elevation of blood glucose levels resulting from impaired insulin secretion, insulin action, or both. The global prevalence of diabetes has increased at an alarming rate, posing a serious burden on healthcare systems worldwide. Prolonged hyperglycemia leads to structural and functional damage in various organs, ultimately giving rise to long-term complications that significantly reduce quality of life and increase morbidity and mortality among diabetic patients.

Diabetic complications are broadly categorized into microvascular and macrovascular disorders. Microvascular complications include diabetic retinopathy, nephropathy, and neuropathy, while macrovascular complications encompass cardiovascular diseases such as coronary artery disease and stroke. In addition, delayed wound healing and diabetic foot ulcers represent major clinical challenges due to their high risk of infection and limb amputation. These complications arise from multiple interrelated mechanisms, including oxidative stress, chronic inflammation, advanced glycation

end product (AGE) formation, endothelial dysfunction, and impaired cellular signaling pathways.

Although conventional pharmacological therapies play a crucial role in controlling blood glucose levels, they are often insufficient in preventing or reversing diabetes-related complications. Long-term use of synthetic drugs may also be associated with adverse effects, drug resistance, and reduced patient compliance. Consequently, there is growing interest in alternative and complementary therapeutic approaches that target multiple pathogenic pathways involved in diabetic complications.

Medicinal plants have been traditionally used for the management of diabetes and its associated disorders due to their therapeutic efficacy and relatively favorable safety profiles. Among them, *Moringa oleifera*, a widely cultivated plant in tropical and subtropical regions, has gained considerable attention for its nutritional and medicinal value. Various parts of the plant, including leaves, seeds, bark, and pods, are rich in bioactive compounds such as polyphenols, flavonoids, alkaloids, vitamins, and minerals.

Emerging scientific evidence suggests that *Moringa oleifera* exerts protective effects against diabetes-induced organ damage through antioxidant, antiinflammatory, antihyperglycemic, and cytoprotective mechanisms. Beyond glycemic control, the plant has demonstrated therapeutic potential in mitigating diabetic retinopathy, nephropathy, neuropathy, and impaired wound healing. This review aims to critically analyze current literature on the role of *Moringa oleifera* in targeting diabetic complications, with emphasis on its pharmacological mechanisms and experimental and clinical findings.

➤ *Causes of Diabetes Include:*

- Insulin resistance
- Autoimmune disease
- Hormonal imbalances
- Pancreatic damage
- Genetic mutations

➤ *Classification*

• *Diabetes Mellitus Type-1*

- ✓ Other Name: Insulin Dependent Diabetes Mellitus (IDDM) or Juvenile diabetes
- ✓ Onset: Sudden Age at onset children
- ✓ Cause: Autoimmune or pancreatic cells unable to produce insulin due to complete destruction of beta cells of pancreas. Tends to develop at a young age, cannot be prevented. Type-1 requires lifelong exogenous insulin. It mostly occurs in children and clients looking as thin. Diabetes ketoacidosis (DKA) is commonly seen in type-1 diabetes

- ✓ Risk factors: genetic causes, toxins, virus, age younger than 30 years

• *Diabetes Mellitus Type-II*

- ✓ Other Name: Non-Insulin Depended Diabetes Mellitus (NIDDM).
- ✓ Onset: Gradual Age at onset: adults
- ✓ Cause: Insufficient insulin secretion or insulin resistance
- ✓ It may be controlled with dietary modifications, exercises, oral hypoglycaemic agents. It mostly occurs in adults, more prone in obese adult.
- ✓ Risk factors: most common-obesity & lack of exercise, others history of gestational

• *Gestational Diabetes*

Rare form of diabetes which occurs in women during pregnancy. Detected during 24-28 weeks of gestations. (IIT Kharagpur-2018) Usually it will resolve within 6 weeks after gestation. Clinical features in a newborn who is born by GDM mother.

- ✓ Macrosomia: Large baby usually >4000 gm due to insulin resistance of the mother.
- ✓ Hypoglycaemia: Due to hyperglycemic intrauterine environment leads to a relative increase in fetal insulin secretion which cause low sugar level (hypoglycaemia) in newborn.
- ✓ Hypocalcaemia: Due to immature parathyroid gland in newborn. Hyperbilirubinemia: High level of bilirubin due to immature liver & RBC's

➤ *Pathophysiology*




Fig 1 Pathophysiology of Diabetes Mellitus

➤ *Symptoms*

Diabetes symptoms depend on how high your blood sugar is.

- *Some of the Symptoms of Type 1 Diabetes and Type 2 Diabetes are:*

- ✓ Polydipsia
- ✓ Frequent urination

- ✓ Weight loss
- ✓ Presence of ketones in the urine
- ✓ Feeling tired and weak.
- ✓ Feeling irritable or having other mood changes.
- ✓ Having blurry vision.
- ✓ Having slow-healing sores.
- ✓ Getting a lot of infections, such as gum, skin and vaginal infections.




Fig 2 Symptoms of Diabetes Mellitus

➤ *Diagnosis of Diabetes Mellitus*

BLOOD SUGAR LEVEL CHART			
	FASTING	JUST ATE	3 HOURS AFTER EATING
NORMAL	80-100	170-200	120-140
PRE-DIABETIC	101-125	190-230	140-160
DIABETIC	126+	220-300	200+

Fig 3 Blood Sugar Level Chart

➤ *Complication of Diabetes Mellitus:*

- Diabetic retinopathy

- Diabetic nephropathy
- Diabetic neuropathy
- Diabetic foot




Fig 4 Complication of Diabetes Mellitus

A. Pathophysiology of Complications of Diabetes Mellitus:

Chronic hyperglycaemia in diabetes mellitus leads to microvascular and macrovascular damage via oxidative stress, inflammation, advanced glycation end-products

(AGEs), polyol pathway activation, protein kinase-C activation, and endothelial dysfunction. These mechanisms culminate in long-term complications affecting the eyes, kidneys, nerves, and skin/wound healing.




Fig 5 Mechanism of Diabetic Complication

➤ *Diabetic Retinopathy (DR)*

- *Overview*

Diabetic retinopathy is a microvascular complication and a leading cause of preventable blindness among working-age adults. It results from prolonged hyperglycemia-induced damage to retinal capillaries.

- *Pathophysiology*

- ✓ Chronic hyperglycemia → ↑ AGEs and ROS
- ✓ Damage to retinal pericytes and endothelial cells
- ✓ Capillary basement membrane thickening
- ✓ Increased vascular permeability and ischemia
- ✓ Activation of VEGF → pathological neovascularization

- *Stages*

Non-Proliferative Diabetic Retinopathy (NPDR)

- ✓ Microaneurysms
- ✓ Dot-blot hemorrhages
- ✓ Hard exudates

- *Proliferative Diabetic Retinopathy (PDR)*

- ✓ Neovascularization
- ✓ Vitreous hemorrhage
- ✓ Retinal detachment

- *Clinical Features*

- ✓ Blurred vision
- ✓ Floaters
- ✓ Impaired color vision
- ✓ Vision loss (late stage)

- *Molecular Markers*

- ✓ VEGF
- ✓ ICAM-1
- ✓ TNF- α
- ✓ IL-6
- ✓ Oxidative stress markers (MDA)

- *Therapeutic Insight*

- ✓ Anti-VEGF agents
- ✓ Antioxidants & anti-inflammatory phytochemicals
- ✓ Nutraceuticals with retinal protective effects (e.g., flavonoids)

- *Figure 1 (Suggested)*

“Pathogenesis of Diabetic Retinopathy” Hyperglycemia → oxidative stress → microvascular damage → VEGF-mediated neovascularization → vision loss

➤ *Diabetic Nephropathy (DN)*

- *Overview*

Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) worldwide and develops due to progressive glomerular and tubular injury.

- *Pathophysiology*

- ✓ Hyperglycemia → glomerular hyperfiltration
- ✓ Mesangial cell expansion
- ✓ Thickening of glomerular basement membrane
- ✓ Podocyte loss
- ✓ Activation of RAAS and inflammatory cytokines

- *Stages*

- ✓ Hyperfiltration
- ✓ Microalbuminuria (30–300 mg/day)
- ✓ Macroalbuminuria (>300 mg/day)
- ✓ Declining GFR
- ✓ End-stage renal disease

- *Clinical Features*

- ✓ Proteinuria
- ✓ Edema
- ✓ Hypertension
- ✓ Reduced urine output (advanced stage)

- *Biomarkers*

- ✓ Albumin-to-creatinine ratio
- ✓ Serum creatinine
- ✓ Estimated GFR
- ✓ TGF- β , NF- κ B

- *Therapeutic Insight*

- ✓ ACE inhibitors / ARBs
- ✓ Anti-fibrotic and antioxidant agents
- ✓ Phytochemicals reducing oxidative and inflammatory renal damage

- *Figure 2 (Suggested)*

“Mechanisms of Diabetic Nephropathy Progression” Hyperglycemia → oxidative stress → mesangial expansion → glomerulosclerosis → renal failure

➤ *Diabetic Neuropathy*

- *Overview*

Diabetic neuropathy is a nerve damage disorder caused by chronic metabolic and vascular abnormalities in diabetes.

- *Types*

- ✓ Peripheral neuropathy (most common)
- ✓ Autonomic neuropathy
- ✓ Proximal neuropathy

- ✓ Focal neuropathy
- *Pathophysiology*
- ✓ Polyol pathway activation → sorbitol accumulation
- ✓ Reduced nerve blood flow
- ✓ Oxidative stress–induced neuronal injury
- ✓ Mitochondrial dysfunction
- *Clinical Features*
- ✓ Tingling and numbness
- ✓ Burning or stabbing pain
- ✓ Loss of sensation (risk of foot ulcers)
- ✓ Muscle weakness
- *Neurochemical Changes*
- ✓ Reduced nerve growth factor (NGF)
- ✓ Increased inflammatory mediators
- ✓ Lipid peroxidation
- *Therapeutic Insight*
- ✓ Pain modulators (gabapentin, duloxetine)
- ✓ Antioxidant and neuroprotective agents
- ✓ Natural compounds improving nerve regeneration
- *Figure 3 (Suggested)*
“Pathophysiology of Diabetic Neuropathy”
Hyperglycemia → oxidative stress → microvascular ischemia → nerve degeneration
- *Diabetic Wound Healing*
- *Overview*
Delayed wound healing in diabetes leads to chronic ulcers, infections, and amputations, particularly in the lower extremities.
- *Pathophysiology*
- ✓ Reduced nitric oxide → poor angiogenesis
- ✓ Impaired fibroblast migration
- ✓ Decreased collagen synthesis
- ✓ Prolonged inflammation
- ✓ High susceptibility to infection
- *Stages Affected*
- ✓ Inflammatory phase (prolonged)
- ✓ Proliferative phase (impaired angiogenesis)
- ✓ Remodeling phase (poor collagen deposition)
- *Clinical Features*
- ✓ Non-healing ulcers
- ✓ Necrosis
- ✓ Secondary infections
- ✓ Gangrene (advanced stage)
- *Key Molecular Factors*
- ✓ VEGF ↓
- ✓ TGF-β ↓
- ✓ ROS ↑
- ✓ Matrix metalloproteinases ↑
- *Therapeutic Insight*
- ✓ Growth factor therapy
- ✓ Antioxidant and anti-microbial agents
- ✓ Herbal formulations enhancing angiogenesis and collagen formation
- *Figure 4 (Suggested)*
“Impaired Wound Healing in Diabetes”
Hyperglycemia → oxidative stress → reduced angiogenesis → delayed tissue repair.
- *Comparative Summary Table*

Table 1 Comparative Summary Table

Complication	Primary Damage	Key Mechanism	Clinical Outcome
Retinopathy	Retina	VEGF, oxidative stress	Vision loss
Nephropathy	Kidney	Fibrosis, RAAS activation	Renal failure
Neuropathy	Peripheral nerves	Ischemia, ROS	Pain, numbness
Wound healing	Skin	Impaired angiogenesis	Chronic ulcers

II. NOVELTY AND SIGNIFICANCE OF THE REVIEW

Most existing reviews on *Moringa oleifera* primarily focus on its hypoglycemic activity. However, diabetic complications are the major contributors to disease burden and are inadequately managed by glucose-centric therapies alone. The novelty of this review lies in its complication-focused perspective, emphasizing the protective role of *Moringa oleifera* against diabetic neuropathy, nephropathy, impaired wound healing, and vascular damage. Furthermore,

this review integrates mechanistic insights with formulation challenges and translational gaps, offering a comprehensive and updated perspective that has not been systematically addressed in previous literature.

➤ *Botanical Overview:*

- Synonyms: Drumstick Tree, Horseradish Tree, and Ben Oil Tree
- Biological source: Leaves, pods, seeds, flowers, and roots of *Moringa oleifera* Lam.

- Geographical Source: Native to India; widely grown in tropical and subtropical regions (India, Africa, Sri Lanka, Philippines, South America).



Fig 6 Moringa Oleifera

➤ *Nutritional Properties of Moringa Oleifera*

Moringa oleifera is a highly nutritious plant known for its rich composition of essential nutrients. The leaves are an excellent source of proteins, containing important amino acids, along with high levels of vitamins such as vitamin A (β -carotene), vitamin C, and vitamin E. It also provides essential minerals including calcium, iron, potassium, and magnesium, which support bone health, hemoglobin formation, and normal metabolic functions. In addition, Moringa oleifera is rich in dietary fiber and natural antioxidants like flavonoids and polyphenols, contributing to its overall nutritional and health-promoting value. These properties make Moringa oleifera a valuable functional food and nutraceutical ingredient.

III. PHYTOCHEMICAL PROFILE OF MORINGA OLEIFERA

Moringa oleifera, belonging to the family Moringaceae, is a fast-growing plant widely distributed in tropical and subtropical regions. It has been traditionally used in various systems of medicine for the treatment of metabolic disorders, infections, inflammation, and nutritional deficiencies. Almost all parts of the plant, including leaves, seeds, flowers, bark, and roots, possess medicinal value and are known for their rich nutritional and therapeutic properties.

Phytochemical investigations have revealed that *Moringa oleifera* is a rich source of biologically active compounds. The leaves contain high concentrations of

flavonoids such as quercetin and kaempferol, phenolic acids, ascorbic acid, carotenoids, and tocopherols, which contribute to its potent antioxidant activity. In addition, alkaloids, tannins, saponins, and glycosides have been identified in various parts of the plant. The seeds are particularly rich in isothiocyanates and glucosinolates, which exhibit anti-inflammatory and cytoprotective effects.

The pharmacological properties of *Moringa oleifera* are closely linked to its diverse phytochemical composition. Numerous experimental studies have demonstrated its antihyperglycemic activity through enhancement of insulin secretion, improvement of insulin sensitivity, and inhibition of intestinal glucose absorption. Beyond glucose regulation, *Moringa oleifera* exhibits strong antioxidant and anti-inflammatory effects, which are critical in counteracting the pathological mechanisms involved in diabetic complications.

Furthermore, the plant has been reported to possess nephroprotective, neuroprotective, hepatoprotective, cardioprotective, and wound-healing properties. These effects are mediated through modulation of oxidative stress, suppression of pro-inflammatory mediators, improvement of endothelial function, and promotion of tissue regeneration. The presence of essential amino acids, vitamins, and minerals further enhances the therapeutic value of *Moringa oleifera*, making it a multifunctional natural agent.

Given its broad spectrum of pharmacological activities and favorable safety profile, *Moringa oleifera* has gained

attention as a promising adjunct therapy for the management of diabetes and its associated complications. Its multi-targeted action makes it particularly suitable for addressing the complex and multifactorial nature of diabetic complications.

➤ *Moringa Oleifera Leaves Contain a Diverse Range of Bioactive Compounds:*

- Flavonoids: Quercetin, kaempferol, rutin

- Phenolic acids: Chlorogenic acid, gallic acid
- Isothiocyanates: Moringin
- Vitamins: Vitamin C, Vitamin E, B-carotene
- Minerals: Calcium, potassium, iron

These compounds collectively contribute to antioxidant defense, inflammation.

Table 2 Bioactive Compounds of Moringa Oleifera and Targeted Diabetic Complications

Bioactive compound	Pharmacological activity
Quercetin	Antioxidant, anti-inflammatory
Chlorogenic acid	Anti-glycation
Isothiocyanates	Cytoprotective
Vitamins C & E	Free radical scavenging

➤ *Mechanisms of Action in Diabetic Complications*

Moringa oleifera mitigates diabetic complications through multiple pathways:

- Scavenging reactive oxygen species and reducing oxidative stress

- Suppressing inflammatory mediators (TNF- α , IL-6, NF-KB)
- Inhibiting AGE formation and protein glycation
- Improving insulin signaling and endothelial function
- Enhancing angiogenesis, collagen synthesis, and tissue regeneration

Mechanisms of Action in Diabetic Complications




Fig 7 Mechanisms of Action of Diabetic Complication




Fig 8 Mechanistic Pathways Through Which Moringa Oleifera Targets Diabetic Complications.

IV. THERAPEUTIC ROLE IN DIABETIC COMPLICATIONS

➤ *Diabetic Retinopathy*

Diabetic retinopathy, therapeutic interventions act by reducing hyperglycemia-induced oxidative stress and inflammation, inhibiting VEGF-mediated neovascularization, protecting retinal microvasculature, and thereby preventing disease progression and vision loss.

➤ *Diabetic Neuropathy*

Oxidative stress-induced neuronal damage is a key factor in diabetic neuropathy. Flavonoids present in Moringa oleifera exhibit neuroprotective effects by reducing lipid peroxidation and improving nerve function.

➤ *Diabetic Nephropathy*

Moringa oleifera demonstrates renoprotective activity by reducing oxidative damage, improving renal biomarkers, and decreasing albuminuria in diabetic animal models.

➤ *Diabetic Wound Healing*

Delayed wound healing in diabetes is associated with impaired angiogenesis and inflammation. Moringa oleifera enhances fibroblast proliferation, collagen deposition, and epithelialization, leading to faster wound closure.

➤ *Future Perspectives / Scope*

- *Important Areas to Explore:*

- ✓ Standardization of extracts and bioactive dosage

- ✓ Well-designed clinical trials targeting complications
- ✓ Molecular and omics studies for mechanistic insights
- ✓ Formulation into nutraceuticals or adjunct therapies.

V. CONCLUSION

While Moringa oleifera exhibits promising multi-targeted effects beyond glycemic control, especially in ameliorating mechanisms central to diabetic complications, definitive clinical evidence remains sparse. Preclinical data support antioxidant, anti-inflammatory, lipid-modulating, vascular-protective, and wound-healing actions. With growing interest in integrative therapies, *M. oleifera* warrants rigorous clinical investigation as an adjunctive strategy in comprehensive diabetic care.

REFERENCES

- [1]. Mthiyane, F. T., et al. (2024). A review on the antidiabetic properties of Moringa oleifera extracts: focusing on oxidative stress and inflammation. *Molecules*, 29(10): 2237. <https://pubmed.ncbi.nlm.nih.gov/35899107/>
- [2]. Daba, M. (2020). Nutritional composition and antioxidant properties of Moringa oleifera. *Asian Pac J Trop Biomed*, 8(7): 289-297. <https://pubmed.ncbi.nlm.nih.gov/39849793/>
- [3]. Sidney JS, Michael JH; First published: 24 March 2015; Review of the Safety and Efficacy of Moringa oleifera ;Volume 29 page no. 796-804. <https://doi.org/10.1002/ptr.5325>

- [4]. Leone, A., et al. (2015). Nutritional properties and antioxidant capacity of moringa powders. *Phytotherapy Research*, 29(3): 295–305. <https://pubmed.ncbi.nlm.nih.gov/25620073/>
- [5]. Gupta, R., et al. (2020). Anti-diabetic and antioxidant activities of *Moringa oleifera* leaves: an overview of evidence. *Phytomedicine*, 68: 153217. <https://pubmed.ncbi.nlm.nih.gov/32035982/>
- [6]. Vergara-Jimenez, M., et al. (2017). Bioactive components in *Moringa oleifera* leaves protect against chronic disease. *Antioxidants*, 2(4): 189–210. <https://pubmed.ncbi.nlm.nih.gov/28684661/>
- [7]. Saini, R. K., et al. (2016). Nutritional, therapeutic, and processing aspects of *Moringa oleifera* leaves. *Front Pharmacol*, 7:32. <https://pubmed.ncbi.nlm.nih.gov/27089374/>
- [8]. Gopalakrishnan, L., et al. (2016). Miracle tree: review on nutritional and medicinal properties of *Moringa oleifera*. *Food Science and Human Wellness*, 5(2): 49–56. <https://doi.org/10.1016/j.fshw.2016.04.001>
- [9]. Fuglie, L. (1999). The Miracle Tree: Leaves of *Moringa oleifera*. Dakar:Church World Service.
- [10]. Jaiswal, D., et al. (2009). Hypoglycemic and antihyperglycemic effect of *M. oleifera* Lam. *Indian J Clin Biochem*, 24(1): 88–95. <https://pubmed.ncbi.nlm.nih.gov/23105989/>
- [11]. Mbikay, M. (2012). Therapeutic potential of *Moringa oleifera* leaves in chronic hyperglycemia. *Int J Food Sci Nutr*, 13(1): 1-7. <https://pubmed.ncbi.nlm.nih.gov/22499423/>
- [12]. Tende, J., et al. (2012). Hypoglycemic effects of *Moringa oleifera* leaf extract. *Acta Vet Brno*, 81: 349–353. <https://pubmed.ncbi.nlm.nih.gov/26344723/>
- [13]. Ndong, M., et al. (2007). Effects of *Moringa oleifera* leaf powder on glucose tolerance. *Journal of Food Science and Technology*, 42(1): 10–15. <https://pubmed.ncbi.nlm.nih.gov/19070160/>
- [14]. Trimigno, L., et al. (2020). Clinical evidence on moringa and metabolic syndrome. *Nutrients*, 12(7). <https://www.mdpi.com/2072-6643/12/7/2050>
- [15]. Kumbhare, D. M., et al. (2021). Animal studies show benefits of moringa on glucose metabolism. *J Food Sci Technol*, 58: 123.
- [16]. Bais, S., et al. (2023). *Moringa oleifera* extract ameliorates diabetic retinopathy via oxidative stress inhibition. *Journal of Ethnopharmacology*, 302: 115000. <https://www.sciencedirect.com/science/article/abs/pii/S0254629923005720>
- [17]. Batiha, G., et al. (2021). Antioxidant properties of *Moringa* in prevention of diabetic retinopathy. *Biomedicine & Pharmacotherapy*, 138: 111452.
- [18]. Ahmad, S., et al. (2024). Protective effect of *M. oleifera* against diabetic nephropathy. *Phytochemistry Reviews*. <https://link.springer.com/article/10.1007/s11101-024-09927-x>
- [19]. Aja, P. M., et al. (2014). Renoprotective effect of *Moringa oleifera* leaves in diabetic rats. *Int J Biochem Res Rev*, 5(1): 83–90.
- [20]. Iqbal, S., et al. (2023). Neuroprotective effects of *M. oleifera* in diabetic rats. *Biomedicines*, 13(3): 634. <https://www.mdpi.com/2227-9059/13/3/634>
- [21]. Aslam, M., et al. (2023). *Moringa oleifera* in wound healing and angiogenesis. *Biomedical Journal of Scientific and Technical Research*, 50(5): 39990. <https://biomedres.us/fulltexts/BJSTR.MS.ID.008249.php>
- [22]. MAYFIELD J ,1998; Classification of Diabetes mellitus, Volume 58(6):page no.1355-1362.
- [23]. Schuster DP, Duvuuri V; Diabetes Mellitus, Volume 19 , Issue 1,Pages 1193, January 2002.
- [24]. Anwar F, Latif S, Ashraf M, and Gilani AH, 2007; *Moringa oleifera*: a food plant with multiple medicinal uses. *Phytotherapy Research*; Volume 21(1): page no.17-25.
- [25]. Abdulkadir, A. R., et al. (2019). *Moringa* extract stimulated wound healing in diabetic rats. *J Diabetes Metab Disord*, 18: 129–138.
- [26]. ADA. (2021). Classification and Diagnosis of Diabetes. *Diabetes Care*, 44(Suppl 1): S15–S33.
- [27]. American Diabetes Association. Standards of care in diabetes. *Diabetes Care*, 45(Suppl1).
- [28]. DeFronzo, R. A. (2009). Pathogenesis of type 2 diabetes mellitus. *Diabetes*, 58(4): 773–795.
- [29]. Nathan, D. M. (2015). Diagnosis of diabetes. *Lancet*, 386: 1463–1464.
- [30]. Brownlee, M. (2005). The pathobiology of diabetic complications. *Nature*, 414(6865): 813–820.
- [31]. Forbes, J., et al. (2008). Oxidative stress and diabetic complications. *Pharmacol Rev*, 60(1): 144–175.
- [32]. Klein, R., et al. (2008). Epidemiology of diabetic retinopathy. *Diabetes Care*, 31: 190–191.
- [33]. Fioretto, P., et al. (2010). Diabetic nephropathy: microvascular complications. *N Engl J Med*, 370: 2294–2303.
- [34]. Tesfaye, S., et al. (2010). Neuropathy in diabetes. *Lancet Neurology*, 9:521–534.
- [35]. Saini, R. K., et al. (2014). *Moringa* phytoconstituents: Pharmacological profile. *J Food Sci Technol*, 51: 214–230.
- [36]. Anwar, F., et al. (2007). *Moringa*: A food plant with multiple medicinal uses. *Phytotherapy Research*, 21: 17–25.
- [37]. Coppin, J. P., et al. (2013). Micronutrients in *Moringa oleifera*. *Journal of Food Composition and Analysis*, 30: 107–112.
- [38]. Gupta, S., et al. (2012). Mechanisms of *Moringa oleifera* in metabolic disease. *Asian Pac J Trop Med*, 5(5): 423–427.
- [39]. Upadhyay, A., et al. (2022). Isothiocyanates from moringa as antiinflammatory agents. *Journal of Medicinal Chemistry*, 65(5):2988–3002.
- [40]. Rahman, H., et al. (2021). *Moringa* phytochemicals modulate metabolic pathways. *Fitoterapia*, 150: 104–156.
- [41]. Abdulkadir, A. (2018). Antioxidant defense mechanisms of moringa. *Food Chemistry*, 225: 70–77
- [42]. Waterhouse, A., et al. (2017). Effects of moringa on insulin resistance: clinical trial. *J Diabetes Metab*, 8(2): 1–6.

- [43]. Patel, S., et al. (2021). Effects of moringa supplementation on metabolic syndrome. *Nutrients*, 13(7): 2457.
- [44]. Olayaki, L. A., et al. (2015). Hypoglycemic effects of *Moringa oleifera* leaves in diabetic rats. *J Basic Clin Physiol Pharmacol*, 26(6):603–608.
- [45]. Tahiliani, P., et al. (2000). Insulin secretagogue effect of moringa leaves. *Indian J Physiol Pharmacol*, 44: 207–210.
- [46]. Kiranmai, M., et al. (2012). Moringa enhances effects of metformin. *Pharmacognosy Res*, 4(1): 1–5.
- [47]. Patel, K., et al. (2021). Phyto-pharmaceutical synergy in diabetes treatment. *Biomed Pharmacother*, 146: 112507.
- [48]. Awodele, O., et al. (2012). Toxicity profile of *Moringa oleifera* extracts. *Nigerian J Pharmaceutical Sci*, 11(2): 28–32.
- [49]. Kasolo, J., et al. (2011). Acute toxicity studies of moringa leaf extract. *J Pharmacogn Phytother*, 2(7): 89–94.
- [50]. Singh, R., et al. (2009). Anti-inflammatory activity of moringa. *Indian J Exp Biol*, 47: 354–357.
- [51]. Chumark, P., et al. (2008). Cardiovascular antioxidant effects of moringa. *J Ethanopharmacol* 116(3): 439–446.
- [52]. Nouman, W., et al. (2016). Potential role of *M. oleifera* in oxidative stress. *Asian Pac J Trop Biomed*, 5: 375–380.
- [53]. Badar, T., et al. (2019). Systems biology of phytomedicine in diabetes. *Front Pharmacol* 10: 841.
- [54]. Lee, H., et al. (2020). Omics approaches to diabetes phytomedicine. *Biomed Pharmacother*, 132: 110823.
- [55]. Vinayagam, R., et al. (2016). Nutraceutical approach in metabolic syndrome. *Nutrition*, 32(1): 1–5.
- [56]. Popoola, S. O., et al. (2021). Pharmacological activities of *M. oleifera* in diabetes. *J Diabetes Metab* 12:601.
- [57]. Chukwuma, C., et al. (2019). Contribution of antioxidants in diabetes management. *Int J Mol Sci*, 20(18): 4521.
- [58]. Ali, S., et al. (2017). Role of phytochemicals in oxidative stress in diabetes. *Drug Discov Ther*, 11(3): 116–122.
- [59]. Jung, U. J., et al. (2011). Oxidative stress and diabetes: novel strategies. *BioFactors*, 37(2): 82–91.
- [60]. Rhee, S. Y., et al. (2010). Epidemiology of diabetes. *Diabetes Metab J*, 34(1): 1–7.
- [61]. Zimmet, P., et al. (2001). Global epidemiology of diabetes. *Nature*, 414(6865): 782–787.
- [62]. International Diabetes Federation. (2021). *Diabetes Atlas* 10th Ed.
- [63]. WHO. (2019). Classification of diabetes mellitus.